| 前收盘价格 | 0.140 |
| 收盘价格 | 0.145 |
| 成交量 | 5,139 |
| 平均成交量 (3个月) | 478,451 |
| 市值 | 39,859,404 |
| 价格/销量 (P/S) | 1.20 |
| 股市价格/股市净资产 (P/B) | 2.14 |
| 52周波幅 | |
| 利润日期 | 25 Aug 2025 - 29 Aug 2025 |
| 营业毛利率 | -32.78% |
| 营业利益率 (TTM) | -41.67% |
| 稀释每股收益 (EPS TTM) | -0.040 |
| 季度收入增长率 (YOY) | 27.50% |
| 总债务/股东权益 (D/E MRQ) | 19.43% |
| 流动比率 (MRQ) | 1.84 |
| 营业现金流 (OCF TTM) | -7.26 M |
| 杠杆自由现金流 (LFCF TTM) | -4.73 M |
| 资产报酬率 (ROA TTM) | -21.93% |
| 股东权益报酬率 (ROE TTM) | -49.77% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (AU) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | NOVA EYE FPO [EYE] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -1.5 |
| 平均 | 0.38 |
|
Nova Eye Medical Ltd is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of its revenue from the United States of America. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 15.14% |
| 机构持股比例 | 18.28% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合